Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
In this large, prospective, global patient cohort, no differences were observed in clinical parameters, prognosis, or differential benefit from palbociclib between HER2-0 and HER2-low tumors. Significant geographic variability was observed in the prevalence of HER2-low status, suggesting a high degree of variation in pathologic assessment of HER2 expression without impact on outcomes.
Authors
- Angela M. DeMichele (ORCID: https://orcid.org/0000-0003-1297-4251)
- Dominik Hlauschek (ORCID: https://orcid.org/0009-0009-1009-3777)
- Christian Fridolin Singer (ORCID: https://orcid.org/0000-0003-1294-0027)
- Michael Gnant (ORCID: https://orcid.org/0000-0003-1002-2118)
- Tufia C. Haddad (ORCID: https://orcid.org/0000-0001-8226-3581)
- Guilherme Nader Marta (ORCID: https://orcid.org/0000-0001-7864-3637)
- Christian Fesl (ORCID: https://orcid.org/0000-0001-5631-076X)
- Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
- Zbigniew Ireneusz Nowecki (ORCID: https://orcid.org/0000-0001-7706-8191)
- Patrick G. Morris (ORCID: https://orcid.org/0000-0002-6055-5273)
- Erica L. Mayer (ORCID: https://orcid.org/0000-0001-5430-8957)
- Evandro de Azambuja (ORCID: https://orcid.org/0000-0001-9501-4509)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Lidija Soelkner
- Georg Pfeiler (ORCID: https://orcid.org/0000-0002-4763-9165)
- Marija Balić (ORCID: https://orcid.org/0000-0001-9482-9191)
- Justin Micah Balko (ORCID: https://orcid.org/0000-0002-4263-5974)
- Yuan Liu (ORCID: https://orcid.org/0000-0003-1835-6147)
- Miguel Martı́n (ORCID: https://orcid.org/0000-0002-2036-1853)
- Arlene Chan
- S. Loibl
Institutions
- Goethe University Frankfurt (DE)
- Université Libre de Bruxelles (BE)
- Mayo Clinic (US)
- Harvard University (US)
- University of Pittsburgh (US)
- Pfizer (United States) (US)
- University of Milan (IT)
- Medical University of Graz (AT)
- Curtin University (AU)
- Institut Jules Bordet (BE)
- Hospital General Universitario Gregorio Marañón (ES)
- Cardiovascular Center Bethanien (DE)
- Comprehensive Cancer Center Vienna (AT)
- Cancer Trials Ireland (IE)
- Magee-Womens Hospital (US)
- Dana-Farber Cancer Institute (US)
- UPMC Hillman Cancer Center (US)
- German Breast group (DE)
- Dana-Farber/Harvard Cancer Center (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- Dana-Farber Brigham Cancer Center (US)
- Medical University of Vienna (AT)
- University of Pennsylvania (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1186/s13058-024-01899-2
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Pfizer
- NSABP Foundation
- ECOG-ACRIN Cancer Research Group